Full-Time

Director Clinical Pharmacology

Confirmed live in the last 24 hours

Eikon Therapeutics

Eikon Therapeutics

201-500 employees

Biotech startup developing innovative medicines

Compensation Overview

$217k - $237.5kAnnually

+ Bonus + Equity Compensation

Expert

Newark, NJ, USA + 1 more

More locations: New York, NY, USA

The position requires a minimum of 3 days a week of onsite presence in either California, New York, or New Jersey offices.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
SAS
R
MATLAB
Requirements
  • Post Graduate degree with 10+ years of experience or a Bachelor's degree with 12+ years of experience in Pharmacology, Pharmaceutical Sciences, or a related field
  • Hands-on experience with PKPD modeling software (NONMEM, R, SAS, MATLAB, Phoenix, SimCyp, GastroPlus, etc.) is a must
  • Knowledgeable in quantitative pharmacology and strong hands-on modeling and simulation experience with PK/PD analysis to inform dose selection, safety profile characterization, and product labeling
  • Demonstrated ability to independently plan, organize, and analyze PK/PD data is essential
  • Excellent problem-solving, written and oral communication skills
Responsibilities
  • Support Clinical Pharmacology Project Leads in analyzing data from preclinical, clinical and stand-alone Clinical Pharmacology studies
  • Utilize basic and advanced modeling and simulation techniques to undertake comprehensive Exposure-Response analysis
  • Generate and interpret pharmacokinetic/pharmacodynamic (PK/PD) models to inform dose selection and regimen optimization
  • Undertake diverse scaling approaches to design optimal dosing regimens for First-In-Human and special populations (e.g. pediatrics)
  • Conduct biopharmaceutics data analyses (e.g. dissolution performance) with the objective of translating in vitro formulation performance to in vivo formulation performance in humans
  • Organize, execute, and report M&S independently, as well as present findings in a clear and concise manner to support decision-making
  • Plan, write, and review pharmacometrics aspects in relevant clinical documents such as study protocols, analysis plans, clinical study reports, and regulatory documents
  • While performing core tasks, get trained on diverse Clinical Pharmacology study types and drug development by experienced Project Leads to eventually take on Lead role

Eikon Therapeutics focuses on discovering and developing new medicines in the pharmaceutical industry. The company employs advanced technologies to study biological systems, aiming to identify new drug targets by examining the dynamic aspects of biology rather than just static chemical processes. Their team consists of diverse professionals, including data scientists, chemists, and engineers, which allows them to combine science and engineering to create new therapies that improve and extend life. A key feature of their approach is a proprietary single-molecule tracking (SMT) platform that visualizes protein motion in living cells, enabling them to analyze molecular interactions with high precision. Eikon Therapeutics aims to serve patients with serious diseases by developing effective treatments and generates revenue through the commercialization of these therapies.

Company Size

201-500

Company Stage

Series D

Total Funding

$1.1B

Headquarters

Hayward, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Eikon raised $350.7 million in Series D funding, supporting cancer drug development.
  • The SMT platform aligns with the growing demand for precision medicine and personalized therapies.
  • Eikon's AI-driven platform enhances drug discovery, leveraging the trend of AI in biotech.

What critics are saying

  • Increased competition from biotech unicorns like Abogen Biosciences with significant funding.
  • Potential challenges in scaling operations, evidenced by a large office lease in Jersey City.
  • Pressure to deliver on high expectations following substantial Series D funding.

What makes Eikon Therapeutics unique

  • Eikon's SMT platform offers real-time, molecular-resolution measurements of protein movement in living cells.
  • The company integrates AI and advanced automation for large-scale molecular interaction analysis.
  • Eikon's diverse team combines expertise in science, engineering, and technology for innovative therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Medical (premiums covered by Eikon at 95%)

Dental Insurance

Vision Insurance

Mental Health Support

Unlimited Paid Time Off

Paid Holidays

Life Insurance

Enhanced Parental Leave

Daily subsidized lunch program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

5%
Chronicles Magazine
Mar 3rd, 2025
Family office investors demonstrate appetite for innovation and diversity

Another significant entity, Soros Capital - managed by Robert Soros, son of the billionaire George Soros - participated in a $350.7 million financing round for Eikon Therapeutics.

Business Wire
Feb 27th, 2025
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline

Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to a

Stat News
Feb 26th, 2025
Eikon Therapeutics raises $350 million

Eikon Therapeutics, led by former Merck RD head Roger Perlmutter, raised $350 million, bringing its total funding to $1.1 billion. The funds will support the clinical development of cancer drugs, including an immunotherapy in Phase 3 for melanoma and two PARP inhibitors. The financing round included investors like Lux Capital and Alexandria Venture Investments.

BioWorld
Feb 26th, 2025
Eikon raises $350.7M in Series D

Eikon Therapeutics Inc. has closed a $351 million series D funding round, marking the largest venture capital round of 2025 and the first series D of the year. This funding supports Eikon as it enters phase III in cancer treatment development.

Business Wire
Jan 7th, 2025
Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Eikon Therapeutics to present at the 43rd Annual J.P. Morgan Healthcare Conference.